Bodemer, C., Kaszuba, A., Kingo, K., Tsianakas, A., Morita, A., Rivas, E., Papanastasiou, P., Keefe, D., Patekar, M., Charef, P., Zhang, L., Cafoncelli, S., & Papavassilis, C. (2021). secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial. Journal of the European Academy of Dermatology and Venereology, 35, 938–947. http://access.bl.uk/ark:/81055/vdc_100124038242.0x000040